L-histidinol increases the vulnerability of cultured human leukemia and lymphoma cells to anticancer drugs

Anticancer Res. 1993 Nov-Dec;13(6A):2107-12.

Abstract

L-Histidinol, a structural analogue of the essential amino acid L-histidine, enhances the toxicity of a variety of anticancer drugs for many tumor cells of animal origin. In this study, the effects of L-histidinol on the proliferation and anticancer drug susceptibility of two human tumor cell lines of lymphoid origin, Daudi and MOLT 4, have been examined. L-Histidinol increased the inherent capacity of six different antineoplastic agents to kill these human tumor cells, in a dose- and time-dependent manner, in spite of the observation that it slowed cell cycle progression in both lines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / toxicity*
  • Carmustine / toxicity
  • Cell Cycle / drug effects
  • Cell Division / drug effects
  • Cell Line
  • Cell Survival / drug effects*
  • Cisplatin / toxicity
  • Daunorubicin / toxicity
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Fluorouracil / toxicity
  • Histidinol / pharmacology*
  • Humans
  • Kinetics
  • Leukemia
  • Lymphoma
  • Time Factors
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Histidinol
  • Cisplatin
  • Fluorouracil
  • Carmustine
  • Daunorubicin